Literature DB >> 7615097

The luteinizing hormone surge--the final stage in ovulation induction: modern aspects of ovulation triggering.

Z Shoham1, M Schacter, E Loumaye, A Weissman, M MacNamee, V Insler.   

Abstract

OBJECTIVE: To compile updated information regarding gonadotropin secretion, specifically the physiology of the midcycle LH surge, in natural cycles and under various ovulation induction protocols. DATA IDENTIFICATION AND SELECTION: Studies that deal with the clinical aspects of LH surge manipulation or substitution were identified through literature and Medline searches.
RESULTS: Three major regulatory factors have been identified as participants in the induction of the midcycle gonadotropin surge. These are hypothalamic GnRH secretion, ovarian and adrenal steroids, and less well-characterized ovarian peptide hormones. Gonadotropin-releasing hormone pulsatility is regulated by a complex mechanism that integrates multiple neurotransmitters and sex steroids. Estradiol plays a central role in the pituitary secretion of LH, which also is influenced by P concentrations. Gonadotropin surge attenuating factor also has been implicated in the regulation of timing and amplitude of the LH surge. Human chorionic gonadotropin is used extensively as a LH surrogate, but its use is associated with a number of disadvantages. Induction of an endogenous LH surge through use of the flare effect of GnRH analogues has been examined more recently and has been found to have several advantages. Recombinant human LH is in the final stages of clinical testing.
CONCLUSION: Although much is known about the physiology of the midcycle LH surge and its variations under different clinical conditions, new approaches to the induction or substitution of the LH surge currently are being examined and learned. The introduction of recombinant gonadotropins into clinical practice is likely to influence ovulation induction and IVF practice to a significant degree in the near future.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7615097     DOI: 10.1016/s0015-0282(16)57717-6

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  12 in total

Review 1.  The role of luteinizing hormone activity in controlled ovarian stimulation.

Authors:  N Angelopoulos; A Goula; G Tolis
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

2.  Low plasma levels of hCG after 10,000-IU hCG injection do not reduce the number or maturation of oocytes recovered in patients undergoing assisted reproduction.

Authors:  S al-Hassan; S Fishel; S Fleming; S Thornton
Journal:  J Assist Reprod Genet       Date:  1998-11       Impact factor: 3.412

Review 3.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

4.  Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series.

Authors:  Bülent Gülekli; Funda Göde; Zerrin Sertkaya; Ahmet Zeki Işık
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

5.  Effects of two human chorionic gonadotropin doses administered to the ovarian states during the in vitro fertilization and embryo transfer program.

Authors:  Mingxing Ma; Jialin Wang; Lijun Xu; Qinxi Zhang; Botao DU; Xiaoying Jiang; Qingli Shi; Lili Zhou; Baoxin Li; Hidekazu Saito; Hirohisa Kurachi
Journal:  Biomed Rep       Date:  2014-11-20

6.  Hypothalamic-pituitary suppression with oral contraceptive pills does not improve outcome in poor responder patients undergoing in vitro fertilization-embryo transfer cycles.

Authors:  P Kovacs; P E Barg; B R Witt
Journal:  J Assist Reprod Genet       Date:  2001-07       Impact factor: 3.412

Review 7.  Contemporary pharmacological manipulation in assisted reproduction.

Authors:  Judith A F Huirne; Cornelis B Lambalk; Andre C D van Loenen; Roel Schats; Peter G A Hompes; Bart C J M Fauser; Nick S Macklon
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Early hCG addition to rFSH for ovarian stimulation in IVF provides better results and the cDNA copies of the hCG receptor may be an indicator of successful stimulation.

Authors:  Peter Drakakis; Dimitris Loutradis; Apostolos Beloukas; Vana Sypsa; Vasiliki Anastasiadou; George Kalofolias; Helen Arabatzi; Erasmia Kiapekou; Konstantinos Stefanidis; Dimitris Paraskevis; Antonis Makrigiannakis; Angelos Hatzakis; Aris Antsaklis
Journal:  Reprod Biol Endocrinol       Date:  2009-10-13       Impact factor: 5.211

9.  "hCG priming" effect in controlled ovarian stimulation through a long protocol.

Authors:  Panagiotis Beretsos; George A Partsinevelos; Eleni Arabatzi; Peter Drakakis; Depy Mavrogianni; Elli Anagnostou; Kostas Stefanidis; Aris Antsaklis; Dimitris Loutradis
Journal:  Reprod Biol Endocrinol       Date:  2009-08-31       Impact factor: 5.211

Review 10.  Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.

Authors:  Philippe Lehert; Efstratios M Kolibianakis; Christos A Venetis; Joan Schertz; Helen Saunders; Pablo Arriagada; Samuel Copt; Basil Tarlatzis
Journal:  Reprod Biol Endocrinol       Date:  2014-02-20       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.